Compartmental analysis of tracer kinetics — from rate constants to Patlak/Logan graphical methods
Positron emission tomography measures the spatial and temporal distribution of a radiolabeled tracer, but the raw image is only a starting point. Compartmental modeling treats tissue as a small number of well-mixed "compartments" exchanging tracer with each other and with arterial plasma according to first-order kinetics — converting a dynamic image series into physiologically meaningful rate constants.
The simplest compartmental model treats the entire tissue region as a single well-mixed pool (C1) exchanging tracer bidirectionally with arterial plasma (Cp):
dC1/dt = K1·Cp(t) − k2·C1(t)
K1 (mL plasma / cm³ tissue / min) describes unidirectional delivery of tracer from blood into tissue, governed by blood flow and, for tracers requiring transport, membrane permeability. k2 (min⁻¹) describes the rate at which tracer washes back out of tissue into plasma.
This model is appropriate for tracers that are not metabolically altered or trapped — the archetypal example is ¹⁵O-labeled water, a freely diffusible flow tracer where K1 closely approximates regional blood flow (mL blood / 100 g tissue / min) because water crosses capillary membranes almost as fast as it is delivered.
Many clinically important tracers, most notably ¹⁸F-fluorodeoxyglucose (FDG), undergo an additional metabolic step after cellular uptake and must be modeled with two tissue compartments — free/exchangeable (C1) and metabolically trapped/bound (C2):
dC1/dt = K1·Cp(t) − (k2 + k3)·C1(t) + k4·C2(t) dC2/dt = k3·C1(t) − k4·C2(t)
Here k3 (min⁻¹) represents the rate of conversion from the free to the trapped pool (for FDG, phosphorylation by hexokinase to FDG-6-phosphate), and k4 (min⁻¹) represents the reverse process (dephosphorylation). For FDG, k4 is small enough over typical 60-minute scan durations to often be approximated as zero — FDG-6-phosphate cannot proceed further through glycolysis and is not readily dephosphorylated, so it accumulates ("metabolic trapping").
Compartmental analysis rests on several simplifying assumptions that are reasonable approximations at the tissue/voxel scale used in PET:
• Each compartment is spatially uniform ("well-mixed") — concentration gradients within a compartment are ignored • All exchange processes follow first-order (linear) kinetics — rate of transfer is proportional to the donor compartment's concentration • Rate constants are assumed constant over the scan duration (steady-state physiology) — problematic if a stimulus or drug changes flow/binding mid-scan • The vascular (blood) contribution to the measured tissue signal is typically modeled explicitly using a fractional blood volume term (Vb ≈ 3–5%) to correct for intravascular activity contaminating the tissue time-activity curve
These assumptions rarely hold perfectly, but the resulting rate constants remain highly reproducible and interpretable, which is why compartmental modeling remains the reference-standard quantitative method against which simplified clinical metrics are validated.
Each rate constant in a compartmental model corresponds to a distinct physiological or biochemical process. Correctly estimating them from noisy, low-temporal-resolution PET data via nonlinear least-squares fitting to the measured tissue time-activity curve is the central technical task of kinetic analysis.
K1 is conventionally written with a capital letter to signal that its units (mL plasma·cm⁻³ tissue·min⁻¹) differ from the other rate constants (min⁻¹) — it converts a plasma concentration into a tissue uptake rate, entangling blood flow (delivery) and, for actively transported tracers, membrane/transporter permeability.
For glucose analogs like FDG, K1 reflects facilitated transport across the cell membrane via GLUT transporters (GLUT1 in most tissues, GLUT3 in neurons, often GLUT1/GLUT3 overexpressed in tumors) combined with regional blood flow delivering tracer to the capillary bed. In well-perfused tissue, K1 is flow-limited; in poorly perfused or transporter-limited tissue, K1 reflects the rate-limiting step of that chain.
k2 (min⁻¹) describes the rate constant for tracer leaving the free tissue compartment and returning to plasma — essentially the reverse transport step. A high k2 means tracer that enters tissue without being metabolized quickly washes back out.
k3 (min⁻¹) is the rate constant for the process converting free tracer into a metabolically trapped or specifically bound form. For FDG, this is phosphorylation to FDG-6-phosphate by hexokinase — the first, rate-limiting step of glycolysis. Elevated k3 in tumors reflects the classic Warburg effect: cancer cells upregulate glycolysis (and hexokinase, particularly hexokinase-II) even in the presence of oxygen, producing the intense FDG uptake that underlies oncologic PET imaging. Typical tumor k3 values (0.02–0.10 min⁻¹) substantially exceed those of most normal tissues.
k4 (min⁻¹) represents the reverse process — de-trapping, e.g. dephosphorylation of FDG-6-phosphate by glucose-6-phosphatase. Because FDG-6-phosphate cannot proceed through the next glycolytic step (it lacks the 2'-hydroxyl group needed for isomerization) and glucose-6-phosphatase activity is low in most tissues (though non-negligible in liver and kidney), k4 is often approximated as zero for typical FDG scan durations of 45–90 minutes.
Rate constants are estimated by nonlinear least-squares fitting: the compartmental differential equations are numerically integrated for candidate parameter values, convolved with the measured arterial input function, and compared against the measured tissue time-activity curve; parameters are iteratively adjusted (e.g., Levenberg-Marquardt algorithm) to minimize the weighted sum of squared residuals.
A persistent challenge is parameter identifiability: K1 and k2 are individually estimable, but their ratio (K1/k2, the distribution volume of the free compartment) is often better determined than either parameter alone, particularly at low temporal sampling density or high measurement noise — common in single-voxel or small-ROI PET data. This motivates the graphical (linearized) analysis methods that estimate composite, more robustly identifiable parameters like Ki and VT directly.
Every compartmental model requires Cp(t), the time-varying tracer concentration in arterial plasma, as its forcing function — without an accurate input function, absolute rate constants cannot be estimated, no matter how good the tissue data is. Measuring Cp(t) accurately is often the most technically demanding part of a kinetic PET study.
The reference method places an indwelling catheter in a peripheral artery (typically the radial artery) to sample blood directly, capturing the true, undelayed, undispersed arterial tracer concentration.
Sampling combines two phases: an automated continuous withdrawal system for the first 1–3 minutes (when Cp(t) rises and falls extremely rapidly following bolus injection, requiring sub-15-second temporal resolution to capture accurately), followed by discrete manual samples at progressively longer intervals as the curve flattens (e.g., at 5, 10, 20, 40, 60, 90 minutes).
Each discrete sample must be centrifuged to separate plasma from whole blood (since PET measures tissue activity referenced to plasma, not whole blood, and the plasma-to-whole-blood ratio is tracer- and hematocrit-dependent), and for tracers that undergo peripheral metabolism, plasma must be further processed by high-performance liquid chromatography (HPLC) to separate the intact parent radiotracer from radiolabeled metabolites — since only the parent compound crosses the blood-brain barrier or is taken up by the target tissue in most models.
Arterial cannulation is invasive, requires trained staff, carries small but real bleeding/infection/vasospasm risk, and is poorly tolerated in some patient populations (children, coagulopathic patients). Image-derived input functions extract Cp(t) directly from the PET images themselves by drawing a region of interest over a large blood pool structure clearly visible in the dynamic images — the left ventricular cavity, ascending aorta, or carotid arteries are common choices.
IDIF approaches must contend with:
• Partial volume effects: PET's limited spatial resolution (~4–6 mm) causes signal from a narrow vessel to blur with surrounding tissue, systematically biasing the measured concentration — worse for smaller vessels like the carotids than for the aorta or LV cavity • Spillover and motion: cardiac and respiratory motion further degrade the apparent blood pool signal, especially problematic for whole-body dynamic protocols • Still typically requires at least a few discrete venous or arterial blood samples for cross-calibration and metabolite correction, since IDIF measures whole blood or total activity, not necessarily metabolite-corrected parent plasma concentration
For some applications, a population-averaged input function shape (derived from prior studies with full arterial sampling), scaled to a small number of individual calibration blood samples, offers a reasonable compromise between invasiveness and accuracy — particularly useful for Patlak-type analyses where only the shape and integral of Cp(t), not its instant-by-instant precision, strongly influences the final Ki estimate.
Regardless of method, errors in the input function propagate directly and often nonlinearly into every downstream rate constant, distribution volume, and influx constant — making input function quality a first-order determinant of the reliability of any kinetic PET study.
Full nonlinear compartmental fitting is computationally demanding and sensitive to noise, especially voxel-by-voxel across an entire PET image. Patlak and Logan graphical analysis exploit the asymptotic linear behavior of compartmental systems under certain tracer-kinetic conditions, converting parameter estimation into simple linear regression.
The Patlak-Gjedde graphical method applies to tracers with effectively irreversible trapping (k4 ≈ 0), the case for FDG. After an initial equilibration period, the compartmental equations predict that plotting:
y(t) = Ctissue(t) / Cp(t) vs. x(t) = ∫₀ᵗ Cp(τ)dτ / Cp(t)
produces a straight line whose slope is Ki, the net influx constant (mL plasma / cm³ tissue / min), and whose intercept relates to the total distribution volume of the reversible compartments.
Ki can be shown analytically to equal K1·k3/(k2+k3) — combining the delivery rate (K1) with the fraction of delivered tracer that becomes irreversibly trapped rather than washing back out (k3/(k2+k3)). Ki relates directly to the regional metabolic rate of glucose via:
MRGlu = (Ki / LC) × [glucose]plasma
where LC is the "lumped constant" — an empirical correction factor (typically ~0.52–0.8 depending on tissue and glucose/insulin conditions) accounting for FDG behaving somewhat differently from native glucose in transport and phosphorylation.
The Patlak plot only becomes linear after transient equilibration between plasma and the reversible tissue compartments — typically requiring exclusion of the first 10–20 minutes of data. Applying it too early biases the estimated Ki.
For tracers with reversible kinetics (k4 meaningfully > 0), most commonly neuroreceptor ligands (e.g., dopamine or serotonin receptor tracers), the Logan graphical method applies. It plots:
y(t) = ∫₀ᵗ Ctissue(τ)dτ / Ctissue(t) vs. x(t) = ∫₀ᵗ Cp(τ)dτ / Ctissue(t)
which becomes linear after equilibration, with slope equal to VT, the total distribution volume — the ratio of tracer concentration in tissue to that in plasma at equilibrium, summing contributions from both the free/nondisplaceable and specifically bound compartments.
For receptor studies using a reference tissue devoid of the target receptor (avoiding the need for arterial sampling entirely), a reference-tissue variant of Logan analysis estimates the distribution volume ratio (DVR = VT(target)/VT(reference)), directly related to receptor binding potential BP = DVR − 1 — the standard outcome measure in neuroreceptor PET pharmacology.
Both Patlak and Logan analysis reduce a multi-parameter nonlinear fitting problem to ordinary linear regression (slope and intercept), which is:
• Computationally fast enough to apply voxel-by-voxel across an entire 3D dynamic PET dataset, producing parametric Ki or VT maps in seconds to minutes • Numerically robust to noise compared to nonlinear least-squares fitting of the full compartmental system, which can suffer from local minima and parameter identifiability problems especially at the single-voxel level • Model-independent in the sense that Ki and VT are macro-parameters that do not require assuming a specific number of compartments — the same Patlak slope emerges whether the underlying system is truly two-compartment or more complex, as long as the irreversibility/equilibration assumptions hold
The tradeoff is that graphical methods discard early-time information and cannot recover the individual micro-rate-constants (K1, k2, k3 separately) — only their combination. When the individual constants themselves are of interest (e.g., distinguishing a delivery vs. trapping abnormality), full nonlinear compartmental fitting is still required.
Despite decades of kinetic modeling methodology, the overwhelming majority of clinical PET scans are interpreted using a single static, semi-quantitative index — the standardized uptake value (SUV) — while full dynamic kinetic modeling remains largely confined to research studies and pharmaceutical drug development. Understanding why illustrates the practical tension between rigor and workflow.
SUV is computed from a single static image acquired at a fixed, standardized time after tracer injection (typically ~60 minutes for FDG):
SUV = Ctissue(t) / (Injected Dose / Body Weight)
This normalizes the measured tissue radioactivity concentration by the administered dose and patient size, producing a simple, unitless number intended to be roughly comparable across patients and over time (e.g., for treatment response assessment).
SUV's appeal is entirely practical: it requires no arterial sampling, no dynamic acquisition, and can be computed from the same single whole-body scan already performed for anatomic localization and staging — fitting seamlessly into a 15–20 minute clinical scan slot. But it is confounded by numerous factors that full kinetic modeling controls for: variability in tracer uptake time between patients, blood glucose level (competitively inhibits FDG uptake), body composition (fat has low uptake, skewing weight-normalized values — leading to alternative normalizations like lean body mass, giving SUL), and partial volume effects in small lesions.
Full kinetic modeling requires a dynamic acquisition from the moment of tracer injection (capturing the rapid early distribution phase) through 60–90 minutes, combined with an arterial or image-derived input function, to estimate K1, k2, k3, (k4), Ki, or VT directly.
This is substantially more resource-intensive: longer scanner occupancy, arterial cannulation and blood processing (or careful IDIF methodology), and more complex data analysis — impractical for routine clinical throughput. In exchange, it provides:
• Genuine absolute quantification independent of uptake-time variability, since the entire time course (not a single snapshot) is modeled • Separation of delivery (K1, flow-related) from trapping/binding (k3, biology-related) — clinically important when a lesion could be under-perfused but highly metabolically active, or well-perfused but metabolically quiescent, distinctions SUV cannot make • The reference measurement against which every simplified clinical metric (SUV, SUVR, simplified kinetic methods) must ultimately be validated
Routine oncologic staging, restaging, and treatment-response PET overwhelmingly uses SUV (or SUV-derived metrics like SUVmax, SUVpeak, metabolic tumor volume, total lesion glycolysis) because the incremental diagnostic value of full kinetic quantification rarely justifies the added scan time and invasiveness for a typical staging question.
Full kinetic modeling remains standard in:
• Neuroreceptor pharmacology research, where DVR/BP from Logan analysis is the accepted outcome measure for characterizing receptor density and occupancy • Pharmaceutical drug development, particularly receptor occupancy studies, where a candidate drug's dose-dependent displacement of a PET tracer from its target must be quantified precisely — SUV-level precision is inadequate • Validation studies establishing that a simplified or static metric adequately approximates the full kinetic gold standard for a specific tracer and application, before that simplified metric is adopted into routine clinical protocols • Research applications explicitly probing the biological meaning of an abnormal signal — e.g., distinguishing flow-limited from metabolism-limited abnormalities in cardiac or neurological PET
Simplified kinetic methods, such as the Patlak plot restricted to late-time data or the "SUV ratio" using tumor-to-reference-tissue ratios, occupy a middle ground — retaining some of kinetic modeling's robustness to uptake-time variability without requiring arterial sampling, and are increasingly used in clinical trials as a practical compromise.